tO survive and spread in vivo through a mechanism that is independent of the T cell system. Such a mechanism might have evolved to prevent the expansion of H-2-deficient variant clones, which would otherwise represent a danger to the organism by escaping T cell recognition after virus infection or malignant transformation 2 (17) . To test this hypothesis, we selected lymphoma cells for loss of H-2 expression and compared these H-2-deficient variants with wild type cells for the ability to grow as tumors in mice. After subcutaneous inoculation into syngeneic mice, the H-2-deficient variants failed to grow out as a solid tumor, whereas the H-2 + control line showed progressive growth at the site of inoculation. 2 In this report, we have analyzed the mechanisms behind this reduced ability to form tumors in vivo. The anti-H-2-resistant and original sublines were compared for in vitro growth parameters, as well as for short-term survival and outgrowth after injection into normal and immunodeficient mice.
Materials and Methods
Animals. Mice of the following inbred strains and F~ hybrids were bred and maintained at the Department of Tumor Biology, Karolinska Institute. C57BL/6, (A.BY × C57BL/6)Fb and (C57BL/6 x C57L)FI, all H-2 wb. Atbymic nu/nu C57BL/6 mice were purchased from Bomholtgaarden, Denmark. All mice were 4-8 wk old at the start of the experiments.
Tumors. RBL-5 is a Rauscher virus-induced T lymphoma, and EL-4 is a benzpyreneinduced T lymphoma. Both are of C57BL/6 (H-2 b) origin. For selection of anti-H-2-resistant lymphoma variants, tumor cells were mutagenized with EMS (ethyl methane sulfonate) (Sigma Chemical Co., St. Louis, MO), 200/~g/ml for 72 h, washed twice, and cultured 1 wk to allow for cell recovery. The cells were then exposed to anti-H-2 alloantisera or mAb, plus rabbit complement (Cedarlane Laboratories, Ltd., Hornby, Ontario, Canada). The surviving cells were expanded and the procedure repeated. Several antibody-complement lytic selections were necessary to obtain stable H-2-1ow variants. All H-2-1ow variants used in this study have been selected at least five times, mAb against H-2K b (28-13-3S) and H-2D b (28-14-8S) were obtained from the American Type Culture Collection, Rockville, MD (18) . All tumors were passaged as ascites lines in H-2-identical C57BL/6 or Fl-hybrid mice. For routine passages, the mice were irradiated (400 rad) 24 h before tumor inoculation, to avoid immunoselection.
Analysis of H-2 Expression. Cell surface expression of H-2 was analyzed on a fluorescence-activated cell sorter (FACS IV; Becton Dickinson Immunocytochemistry Systems, Mountain View, CA). For H-2 analysis, 5 X 105 cells were incubated with murine anti-H-2 mAb (culture supernatants) for 30 rain on ice, washed once, and incubated another 30 min on ice with 200 ~1 fluorescein isothiocyanate (FITC)-labelled rabbit anti-mouse Ig (DAKO, Copenhagen, Demark) diluted 1:10 in balanced salt solution (BSS) supplemented with 20% fetal calf serum (FCS). After three additional washings with BSS, the cells were analyzed on a FACS IV. The frequency and fluorescence of stained cells were determined using a laser output of 200 mW, photo multiplier adjusted to 600 V, and a constant fluorescence gain for each series of samples.
Treatment with Anti-asialo GMl Antiserum. Natural killer (NK) cell deficiency in mice was induced by intravenous injections of rabbit anti-asialo GM1 antibody, Wako Chemicals, Dfisseldorf, Federal Republic of Germany (19) . 30 #1 of the antiserum diluted in 0.2 ml BSS was injected in a tail vein every fourth day, starting one day before tumor challenge. A total of 3-5 injections were given.
In Vivo Rejection Assay with |~5I-UdR-labelled Cells. Tumor cells were labelled intraperitoneally with 125I-5-iodo-2-deoxyuridine (Radiochemical Centre, Amersham Corp., 2 K/irre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. An alternative strategy for self/nonself discrimination? Host resistance directed selectively against lymphoma variants with deleted or reduced H-2 expression. Manuscript submitted for publication. 
Results

Selection and Characterization of Anti-H-2-resistant Lymphoma Variants.
Anti-H-2-resistant variants have been selected from the C57BL/6-derived RBL-5 and EL-4 lymphomas. The wild type lymphoma cells were mutagenized, then exposed to anti-H-2 serum plus complement in several selection cycles to obtain stable variants. In this study, we used selected sublines from two independent mutagenizations of the RBL-5 wild iype line, and one from the EL-4 wild type line. The normal untreated wild type lines, as well as mutagenized but nonselected cell lines, were used as controls (Table I ). All variants used in this study showed a 
Growth and Cloning Efficiency In Vitro.
There was no significant difference between the control lines and the H-2-deficient variants in growth rate after explantation to tissue culture. Growth curves from one of the observations with the RMA H-2 sel line and the unselected RMA control line are shown (Fig. 2) . The lag period before exponential growth, as well as the maximal cell concentration was similar for the two cell lines. Similar results were obtained with the independently selected variants, RMB H-2 sel and EMA H-2 sel; no significant difference with regard to in vitro doubling time, lag periods, nor maximal cell concentration between the wild type control lines and the H-2-selected variants (Table I) .
In addition, no significant differences in cloning efficiency were observed between the control lines and the H-2-selected variants of RBL-5 and EL-4. In two independent experiments, with EMA and EMA H-2 sel, it was possible to observe clones of both cell lines in 50% of the wells 10 d after seeding 4 cells/well. A similar pattern was seen in two independent tests with RMA and RMA H-2 sel, although these lines required seeding of 8 cells/well to get 50% plating efficiency. Tumor Growth in Normal Mice. Different doses of tumor cells (in this study, 103-106 cells) were injected subcutaneously in the flanks of mice in groups of 3-6 animals, usually littermates or otherwise age-matched within 2 wk. Rather than using large groups of mice in single experiments, we chose to use relatively small groups of animals in several independent tests throughout the study. This minimized the risk that random fluctuations in the quality of control and variant cell suspensions would be responsible for differences in the ability to form tumors.
After subcutaneous injections of the mutagenized but nonselected control line RMA (as well as the nonmutagenized RBL-5 line) in doses of >103 cells, these lymphomas always grew out as solid tumors. EMA cells (and the nonmutagenized control, EL-4) were somewhat less malignant, growing in 30-70% of the mice, depending on the injected dose. When tumors appeared, the growth was rapid, and a large solid tumor was palpable within 2-3 wk. The H-2-selected negative variants of RBL-5 and EL-4 (RMA H-2 sel, RMB H-2 sel, and EMA H-2 sel) almost always failed to grow out as solid tumors under the same conditions (Fig.  3) . Doses of >--10 6 cells were needed to get more regular outgrowth of these H-2-deficient cells (not shown). This in vivo difference in tumor growth remained even when the RBL-5 H-2-deficient variant and the control line were injected subcutaneously in the opposite flanks of the same mouse (Table II, o_/la I"1 17
Tumor growth after subcutaneous injections of H-2 ÷ RBL-5 and EL-4 lymphoma lines, and H-2-1ow variants (RMA H-2 sel, RMB H-2 sel, and EMA H-2 sel) in three different doses, in syngeneic C57BL/6 or (C57BL/6 X A.BY)F] mice (one lymphoma type inoculated in each mouse). The bars for H-2 ÷ control lines of RBL-5 and EL-4 each represent pooled data from tests with the untreated wild type lines, or mutagenized but nonselected lines. There were no differences in number of tumor takes or latency periods between the different types of control lines within each tumor. Only the B series of the RBL-5 H-2-variant (RMB H-2 sel) has been tested with l0 b cells. The figures indicate total numbers of mice with tumor growth per total number of mice injected with tumor cells. median latency period 14 d, range 10-35 d). These results suggested that the reduced tumorigenicity of H-2-variant cells was due to a host mechanism that was weakened, but not completely abrogated by 400-rad irradiation.
Tumor Growth in T Cell-deficient Mice. To determine whether the inability of H-2-1ow variant cells to grow out as solid tumors was T cell-dependent, syngeneic nude mice (nu/nu) were inoculated with different doses of H-2-1ow variant and wild type control cells. The tumor cells were injected in separate animals, or in opposite flanks of the same mouse, as described above. Reduced tumorigenicity of the H-2-deficient variant (RMA H-2 sel) was also observed in nude mice. In fact, the nude mice appeared even more resistant, since they remained tumorfree at the RMA H-2 sei inoculation site even after a challenge with 106 cells (Table II, Exp. 5 and 6). Tumor Growth in NK Cell-deficient Mice. To determine whether the failure of the H-2-deficient cells to grow in vivo was dependent upon host NK cell activity, mice were injected with anti-asialo GM1. This antibody is directed against the glycolipid asialo GM1 expressed on the cell surface of NK cells. Microliter amounts of anti-asiaio GM1 depresses NK cell activity in the spleen and other lymphoid organs (19) . Mice were injected every fourth day with 25 ~1 of antibody, In Vivo Survival of lsotope-labeUed Lymphoma Cells. Survival and organ distribution of the H-2 + RBL-5 control line (RMA) and the H-2-1ow variant (RMA H-2 sel) in vivo were studied by monitoring remaining radioactivity in different organs within 12-36 h after intravenous injection of 125I-UdR-prelabelled cells. The 125I-UdR is rapidly released from dead cells, and excreted (20); thus, the amount of radioactivity remaining in each organ indicates the distribution of surviving cells. A 5-100-fold difference was observed in tumor cell survival between the RBL-5 control line and the variant in different experiments. These differences were almost abolished when the mice were pretreated with antiasialo GMI (Fig. 4) . This indicated that NK cell activity was necessary for the rapid elimination of the RBL-5 H-2-1ow variant cells. The effect of anti-asialo GM~ injections was specific, and not due to injection of serum per se, since the 
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differences in survival between the lines were seen also in mice injected with normal rabbit serum (NRS) ( Table III) . The lower counts in liver, spleen, lung, and kidney in mice injected with RMA H-2 sel was not just due to redistribution, since the amount of detectable radioactivity in other organs was negligible. Discussion Three lymphoma variants, selected independently for loss of H-2 expression, showed a significantly reduced ability to form tumors in vivo. In our attempts to analyze the mechanism behind this phenomenon, we failed to find any difference in in vitro growth properties between the variant lymphoma cells and their appropriate controls. The difference observed in vivo must therefore depend on interactions between the tumor cells and host factor(s). One testable interpretation was that the variant and the wild type tumors were in fact equally sensitive to all possible host control mechanisms, and differed only in their ability to evoke a particular systemic host response. The H-2-deficient variant might thus have a unique ability to induce a tumor growth-inhibiting response, or lack the ability to induce a tumor growth-promoting response. These possibilities, however, were excluded in experiments where both tumors were injected simultaneously, in opposite flanks, in the same mouse. Since the difference in tumorigenicity remained under such conditions, it must be due to local tumor-host interactions, or to a difference in sensitivity to the same systemic host factor(s).
Furthermore, the reduced tumorigenicity of the H-2-variant (RMA H-2 sel) did not depend on an intact T cell system. It could be argued that the genetic T cell defect of nude mice is incomplete, since they have CTL precursors detectable under certain conditions in vitro (22) . However, it remains clear that nude mice have a strong relative T cell defect in vivo (23) . Even if the variants were rejected by occasional T cells in nude mice, we would not expect the nude mice to be even more resistant than the wild type mice and be able to reject a challenge of 106 variant cells. Furthermore, while we have been able to protect mice from RBL-5 challenge by preimmunizing them with irradiated cells from this tumor, we have so far not been able to protect mice from RBL-5, nor high doses of the variant cells by preimmunizing with the variants. 2 Taken together, these findings argue against the possibility that variant cells fail to grow because they evoke a strong adaptive T cell response. They are thus different from the highly immunogenic variants of the turn-negative phenotype derived after mutagenization and cloning without selections, as described by several groups (24, 25) .
The strong in vivo resistance of nude mice is reminiscent of earlier findings on their strong rejection potential against certain tumors, attributed to high NK cell activity (26) . Our general conclusion in this study is similar. The effects of whole body irradiation are consistent with rejection mediated by NK cells; an effector population with a limited life span, dependent on radiosensitive precursors, but not necessarily on proliferative expansion after tumor grafting (27) . This would explain the relatively radioresistant rejection of 103 cells, while a dose of 104 cells would outnumber the diminishing effector cell population in the absence of continuous influx from the precursor pool. We thus explain the reduced tumorigenicity of the H-2-variant cells by rapid natural killing in vivo. This was observable within 16-24 h after intravenous injection of radiolabeled cells into the animals. These differences in rapid elimination between the H-2-and the wild type cells were abrogated by anti-asialo GM1 serum, known to reduce NK cell function in vivo (19) . Asialo GM~ is also expressed on a small population of monocytes, and on some immature ceils of T cell lineage (19, 28) . However, taking into account experiments with radiation, nude mice, and natural killing in vivo, the results strongly support a model wherein cells with the functional and phenotypic characteristics of NK cells are responsible for the rejection. It could also be argued that the rapid elimination would be relevant for intravenous disseminated cells only. However, anti-asialo GM~ treatment also allowed the H-2-cells to form tumors after subcutaneous inoculation. At this stage, we conclude that the reduced tumorigenicity is largely, if not entirely due to NK-dependent elimination, regardless of the detailed events leading to the final triggering of tumor cell lysis.
The method based on in vivo rejection of radiolabelled tumor cells in this paper was used previously (29) (30) (31) (32) (33) in studies of hybrid resistance, and showed that leukemic cells failed to survive in the spleens of mice that are not H-2-identical with the transplant (e.g. H-2 b cells in H-2 a'd or H-2 a'b hosts). In previous studies (34, 35) of the RBL-5 lymphoma, we found that it was highly malignant in syngeneic H-2 b'b hosts, whereas it was rejected in H-2 d'b hosts. Thus F1 hybrid resistance (H-2 a'b rejecting H-2 b) and the rejection of syngeneic H-2-deficient cells (H-2 b rejecting H-2-) seem to be mediated by the same mechanism, observable as natural killing within 24 h after intravenous injection, and sensitive to anti-asiaio GM~ (35) . One interpretation, reconciling the two different systems, is that the rejection is dependent upon failure of the grafted cells to present the histocompatibility antigens of the host. NK-mediated rejection of H-2-deficient tumor variants or MHC-disparate bone marrow or lymphoid grafts (36) might then be interpreted to reflect a recognition of incomplete self-H-2 expression z (17) . A surveillance against cells lacking all or a part of self-MHC would also explain why it is relatively difficult to select complete H-2-variants in vivo (37) .
Preferential outgrowth of cells with reduced or deleted expression of certain H-2 alleles has however been observed for some virally induced, strongly antigenic tumors, for which T cells presumably represent the major surveillance mechanism (8, 9, 38) . These experimental systems usually involve transplantation of large cell numbers (i.e. 105 cells or more), and long latency periods, both of which may facilitate suppression of the NK-mediated defense or the acquisition of additional changes of the tumor cells, permitting their escape also from this system. One may compare the progressive growth of 106 H-2-deficient cells in this study, while 10-1,000-fold lower doses could be efficiently rejected in most mice. The lower doses might better correspond to the size of a variant population newly arising in vivo. Escape from a surveillance against incomplete self could occur through selection for increased H-2 expression during tumor progression, thus explaining the paradoxical increase in the expression of class I MHC alleles associated with in vivo growth or metastasis in several experimental systems (5) (6) (7) 15) . It is particularly the (re)expression of D-end alleles that has been associated with the metastatic phenotype (5) (6) (7) . This is interesting if it indeed refects an escape from a defense system that is also responsible for hybrid resistance and related to the NK cells. Both of the two latter phenomena are strongly influenced by genes mapping to the D end of H-2 (31, 32, 39, 40) . In this context, it is interesting that low (or loss of) H-2 expression associated with increased malignancy more frequently involves the K-end locus (7, 8, 38) . In some of the latter systems, recent studies with DNA-mediated gene transfer have provided direct evidence for the role of H-2K genes (38, 41, see also 42). Note however that the presence of H-2 would only be expected to delay or prevent growth of relatively antigenic tumors, probably a minority of spontaneous tumors (10) . The rejection on the basis of H-2 deficiency suggested in this study would be independent of specific tumor antigens.
We have previously suggested that self-H-2 molecules may constitute (or contribute to the recognition of) an inhibitory signal in the NK-target interaction 2 (17) . Lack of inhibitory influence would lead to preferential natural killing of such targets, thus giving the impression of recognition of absence of self. While our results indicate that the H-2-deficient cells are indeed more efficiently rejected by NK cells than their wild type counterparts in vivo, they do not prove the role of H-2 in control of NK sensitivity. At the host level, the NK-mediated elimination could be a nonspecific consequence of earlier events, such as local recruitment and activation of effector cells by H-2-deficient tumor cells, or failure of these cells to home correctly, leading to increased exposure to NK cells. We have recently observed that the H-2-deflcient variants are more susceptible to spontaneous spleen-mediated cytotoxicity than the wild type cells in vitro (RMA: mean 8% lysis, range 0-16%; RMA H-2 sel: mean 28% lysis, range 15-45%). 2 This is in line with the possibility that loss of H-2 expression would affect the natural killing directly, although further studies focusing on the NK-target interaction and the role of other cells are required before any conclusions can be drawn. At the tumor cell level, a direct relation between the H-2-and the NK-sensitive/tum-negative phenotype is attractive, but other possibilities must also be considered. The MHC genes could influence the expression or recognition of other cell surface molecules; our results may also merely reflect a common regulation of MHC genes and genes influencing lymphoma cell interactions with host factors. The role of cell surface H-2 may be directly approached by molecular analysis of the regulatory or structural defects in H-2-variant cells, and by further manipulations of their phenotype using cloned H-2 genes and their derivatives corresponding to truncated (43) or hybrid products (44) .
Summary
Three independent variants with a profound reduction of cell Surface H-2 have been selected from the C57BL/6 mouse-derived RBL-5 and EL-4 T lymphomas. After subcutaneous inoculation of low cell doses in syngeneic mice, the H-2-variants failed to grow out, whereas the H-2 + control lines showed progressive growth. No difference in growth rate or cloning efficiency was detectable in tissue culture. The in vivo difference in tumor outgrowth was analyzed in detail for one of the H-2-1ow lines. The outgrowth difference remained after the H-2-1ow variant and the control line had been injected subcutaneously in opposite flanks of the same mouse, and it was not dependent upon activity of mature T cells, since the same result was seen in athymic nude mice. The difference was partially sensitive to irradiation of the hosts. When mice were pretreated with anti-asialo GM1 antiserum, known to depress natural killer (NK) cell activity, the difference in outgrowth was abolished, and both the control line and the H-2-variant showed progressive growth in vivo. Experiments comparing the distribution and survival of isotope-prelabeled variant and wild type cells indicated that a rapid elimination of the former took place Within 24 h after intravenous injection. These differences in tumor elimination were not seen in mice treated with anti-asialo GM1 antiserum.
We conclude that the reduced tumorigenicity of sublines with impaired H-2 expression is largely, if not exclusively due to rapid elimination by NK cells. These findings may reflect an inverse, indirect relation between factors controlling H-2 expression and NK sensitivity. Another possible explanation is that major histocompatibility complex (MHC)-encoded gene products are directly involved in a regulatory signal in the NK cell system. According to this interpretation, immunological selectivity in the NK cell system would be achieved by the failure to recognize self-MHC, irrespective of the presence of foreign antigens, i.e. by detection of no-self rather than of nonself. This may also explain previous observations on H-2-1inked hybrid resistance against lymphoid grafts and changes in H-2 phenotypes associated with tumor progression.
